All posts in: Uncategorized

Imbed Biosciences Launches MicroLyte® Ag Antimicrobial Matrix Clinical Research Program

Madison, WI, June 5, 2018– Imbed Biosciences, a developer of advanced biomaterials for soft tissue repair and regeneration, today announced the launch of a MicroLyte® Ag Antimicrobial Matrix clinical research program which will comprise multiple sites, studies and a nationwide patient registry.

The first study, underway at Mission Health System in Asheville, NC, is an investigation of MicroLyte® Ag Matrix in complex and non-healing wounds.  Mission Health is coordinating and conducting the 100-patient prospective clinical study, which will assess the efficacy of MicroLyte® Ag Matrix when used in complex skin wounds, including venous stasis ulcers, pressure ulcers, and diabetic foot ulcers.  The primary objective of the study is to determine the percentage of change in the wound size when treated with MicroLyte® Ag Matrix. A secondary objective includes evaluating how long wound closure takes when using MicroLyte® Ag Matrix in the wound. Patients treated with MicroLyte® Ag Matrix are being followed for up to 12 weeks.

MicroLyte® Ag Matrix is a class II medical device which has been 510(k) cleared by the US Food and Drug Administration (FDA). It is a fully-synthetic bioresorbable wound matrix composed primarily of a polyvinyl alcohol sheet with a polymeric surface coating containing ionic and metallic silver. MicroLyte® Ag Matrix is intended for use on partial and full thickness wounds including pressure ulcers, venous stasis ulcers, diabetic ulcers, first and second-degree burns, abrasions and lacerations, donor sites and surgical wounds.  MicroLyte® Ag Matrix may also be used over debrided and grafted partial thickness wounds.  MicroLyte® Ag Matrix works differently than conventional silver-impregnated wound dressings and is designed to be safer and more readily adherent to the varied topography of complex wound beds where potential sources of infection can sequester themselves.   MicroLyte® Ag Matrix uniquely combines bioresorbability and antimicrobial effectiveness in a fully-synthetic product—a first of its kind in the wound care space. Components of the matrix have been shown to support cell growth and vascularization to support wound healing.

Chronic non-healing ulcers are a significant medical problem and the incidence of these wounds is expected to increase as the United States population ages and diabetes becomes more prevalent. The three major subcategories include diabetic foot ulcers (DFU), venous stasis ulcers, and pressure ulcers. The major challenge in the management of open wounds is the reduction of infection causing bacteria. Standard therapies only cure approximately 30 to 50% of DFU after 3 months and approximately 50% of venous stasis ulcers. Pressure ulcers are more difficult as they are associated with immobility, malnutrition and tobacco abuse.

In addition to the chronic wound study at Mission Health, Imbed Biosciences has enrolled several other wound care centers and hospitals, and is seeking additional clinical partners to evaluate MicroLyte® Ag Matrix in other approved indications including burns and surgical applications.  A nationwide patient registry will be established to document and assess the real-world use of MicroLyte® Ag Matrix, as well as economic outcome information.

“Imbed is very pleased to have a world-class healthcare system like Mission Health evaluating MicroLyte Ag and assessing how the product can best help its patients with slow-healing and stalled wounds,” said Imbed’s President and CEO, Ankit Agarwal. “The early results seem very promising, so we are eager see the outcome of this study as well as future studies that we are planning with other clinical partners.”

Institutions interested in participating in the clinical research program should email info@imbedbio.com. Additional information about the study at Mission Health can be found at www.clinicaltrials.gov under identifier NCT03204851. Information about MicroLyte Ag can be found at www.MicroLyteAg.com.

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and soft-tissue repair. The company has a portfolio of products in development based on its patented MicroLyte® matrix polymeric multilayer platform that presents bioactive molecules on tissue surfaces to combat local pain and infections, support soft-tissue repair, and reduce antibiotic/opioid abuse. Imbed is backed by venture capital group WISC Partners based in Madison, WI, and has received research grants from the National Institutes of Health and the National Science Foundation. For more information, please visit www.imbedbio.com, www.MicroLyteAg.com, facebook.com/imbedbio, or @MicroLyteAgMtrx on twitter.

Imbed Biosciences’ Key Patent Claims Granted in Japan

Madison, WI, April 3, 2018– Today Imbed Biosciences, Inc. announced that the Japan Patent Office has granted 14 claims of the company’s Japanese Patent Application No. 2015-541849, titled “Methods and Compositions for Wound Healing.”

The granted claims provide comprehensive coverage to Imbed’s nanometer-thick polymer multilayer matrix technology, which driven by its nanoscale engineering conforms intimately to the soft tissue, including micro-crevices, of surface wounds or internal organs, and is ultimately bioresorbed. This is a groundbreaking scientific advance that has enabled the realization of the long-held dream of engineering the soft tissue for addressing many healthcare challenges including drug delivery with minimal side effects, preventing surgical site infections, and accelerating the healing of acute and chronic/recalcitrant wounds.

The claims granted cover the nanoscale architecture of polymer multilayer matrix, adjacent polymeric layers and a variety of bioactives—including antimicrobial agents, antibiofilm agents, growth factors, hemostatic agents, peptides, anticoagulant, analgesics, or other drugs—that can be incorporated in the matrix and subsequently delivered to the soft tissue in controlled manner for effective therapeutic action.

Based on this technology, Imbed’s first FDA-cleared product MicroLyte® Ag Matrix is available for over-the-counter and Rx purchase on microlyteag.com. MicroLyte® Ag Matrix not only prevents microbial colonization in fresh wounds but also jumpstarts the healing of persistent chronic wounds that have been non-healing for months and years.

For further information, please contact:

Gaurav Pranami, Ph.D.

Vice President of Research & Development

(608) 237-1526

gpranami@imbedbio.com

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and soft-tissue repair. The company has a portfolio of products in development based on its patented MicroLyte® matrix polymeric multilayer platform that presents bioactive molecules on tissue surfaces to combat local pain and infections, support soft-tissue repair, and reduce antibiotic/opioid abuse. Imbed is backed by venture capital group WISC Partners based in Madison, WI, and has received research grants from the National Institutes of Health and the National Science Foundation. For more information, please visit www.imbedbio.com, www.MicroLyteAg.com, facebook.com/imbedbio, or @MicroLyteAgMtrx on twitter.

Imbed Biosciences’ Team Members Honored in List of Health Innovators

Madison, WI, November 7, 2017 – Imbed Biosciences, a developer of advanced biomaterials and wound care devices, is pleased to share that two of its team members—Jeffrey Dalsin, Ph.D. and Robert Beckman—have been named to the 2017 edition of Madison Magazine’s prestigious M-List.  This year, the M-List honors health innovators.  Dr. Dalsin serves as Imbed’s Vice President of Product Development, while Mr. Beckman serves as an outside director on the company’s Board of Directors.

Dr. Dalsin has spent his professional career developing medical technology and serving in leadership roles in start-up companies in Madison.  Prior to joining Imbed a little over a year ago, Jeff previously helped cofound Nerites Corporation, a start-up that commercialized an innovative surgical adhesive and served as Director of Product Development.  In that role, Jeff wore many hats and gained broad start-up operational experience through the company’s successful acquisition in 2011.   Most recently, he led a start-up ultrasound technology company. “I am honored and humbled to be included with such an esteemed group.  I look forward to continuing to help make Madison a leader in health technology,” Dalsin said.

Mr. Beckman, in addition to begin a company director, is currently President and CEO of Wicab Inc, a medical device company developing an assistive device for visually impaired. The device translates digital information from a video camera into gentle electrical stimulation patterns on the surface of the tongue. After a pivotal clinical study, Wicab recently obtained regulatory approvals for marketing the device in the U.S. and Western Europe.  Mr. Beckman was vice president and chief financial officer of Lunar Corp., Madison, WI, and later, of Bone Care International, Middleton, WI. Lunar Corp made machines to screen for bone density, and was acquired by GE Medical in 2000. Bone Care developed drugs to treat a condition that can lead to bone damage in kidney patients, and was bought by Genzyme in 2005.

“Imbed is proud to have two leaders in health innovation among its very talented team.  Both Jeff and Bob bring great experience to our effort, and will be key in ensuring Imbed’s success as the company continues to bring MircoLyte Ag, our FDA-cleared antimicrobial wound dressing, and other innovative products to market,” said Ankit Agarwal, President and CEO of Imbed Biosciences.

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. Company has a portfolio of products in development based on its patented polymeric Microfilm™ platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and support wound healing. Imbed is backed by venture capital group WISC Partners based in Madison, WI. Company has also received research grants from National Institutes of Health and National Science Foundation. For more information, visit www.imbedbio.com and follow facebook.com/imbedbio and @imbedbio on twitter.

 

Imbed Biosciences Advanced Wound Care Portfolio Highlighted SAWC Spring 2017

Imbed Biosciences Advanced Wound Care Portfolio Highlighted SAWC Spring 2017

Madison, WI, April 4, 2017 – Imbed Biosciences, a developer of advanced biomaterials and wound care devices, announced today that the company will present new data and information featuring its MicroLyte™ antimicrobial and antibiofilm wound dressings at the Spring Symposium on Advanced Wound Care (SAWC) in San Diego, CA from April 5-8, 2017. The company will also have a presence in the exhibitor space at booth #1110. SAWC is the nation’s largest interdisciplinary wound care forum.

The company’s poster presentations will highlight research conducted by multi-disciplinary teams internal to Imbed Biosciences, as well as at the University of Wisconsin-Madison, the University of California-Davis, and Mission Hospital (Asheville, NC) including recent clinical outcomes using the company’s breakthrough MicroLyte™ Ag antimicrobial wound dressing on complex chronic wounds. The study is ongoing and involves 100 patients at Mission Hospital with a variety of complex chronic wounds. Imbed will also present veterinary case study outcomes as well as development of a dressing which can reliably eradicate an established biofilm in a wound bed and thus be used in an infected wound.

“The work that will be presented at SAWC represents a wide range of our current research and commercial activities. Meeting attendees will see clinical outcomes in both human and veterinary patients along with results from our early development work on a next generation antibiofilm product,” said Ankit Agarwal, President and CEO of Imbed Biosciences.

Additionally, prospective users will get a first-look at Imbed’s groundbreaking, FDA-cleared MicroLyte™ Ag ultrathin, antimicrobial wound dressing. MicroLyte™ Ag has only a fraction of the silver of competitive dressings, leading to lower incidences of tissue staining and toxicity while still maintaining high antimicrobial activity. FDA cleared MicroLyte™ Ag for use for up to three days in acute wounds such as, lacerations, skin tears, abrasions, surgical wounds (donor and graft sites, incisions), partial thickness first and second degree burns, and partial to full-thickness dermal ulcers such as, diabetic, decubitus, venous stasis, arterial stasis ulcers.

Poster presentations of interest include:

Ultrathin Hydrogel Dressings Containing Gallium Ions and Silver Nanoparticles for the Elimination of Biofilms
G. Pranami1, T. B. Nelson1, E. C. Crawford1, J. L. Dalsin1, M. H. Herron2, C. J. Czuprunski3, N. L. Abbott2, A. Agarwal1,2
1Imbed Biosciences Inc., Madison, WI, USA; 2Department of Chemical Engineering, University of Wisconsin-Madison; 3School Of Veterinary Medicine, University of Wisconsin-Madison

Use of an antimicrobial microfilm wound dressing in spontaneous wounds in animals
Jonathan F. McAnulty, DVM, PhD1 and Michael J. Schurr, MD2
1Department of Surgical Sciences, University of Wisconsin – Madison, WI; 2Mission Hospital, Asheville, NC

Ultrathin Dissolvable Antimicrobial Wound Dressing Is Safe and Effective In Patients With Complex Chronic Wounds
David Humphrey, MD1, Michael J. Schurr, MD2, William Shillinglaw MD1
1Mission Hospital, Asheville NC; 2MAHEC Department of Surgery, Asheville, NC

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. Company has a portfolio of products in development based on its patented polymeric Microfilm™ platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and support wound healing. Imbed is backed by venture capital group WISC Partners based in Madison, WI. Company has also received research grants from National Institutes of Health and National Science Foundation. For more information, visit www.imbedbio.com and follow facebook.com/imbedbio and @imbedbio on twitter.

Imbed Bio Recruits Jeffrey Dalsin To Lead Product Development

IMBED BIO RECRUITS JEFFREY DALSIN TO LEAD PRODUCT DEVELOPMENT

Madison, WI, October 1, 2016 – Imbed Biosciences, a developer of advanced biomaterials and wound care devices, announced today that Jeffrey Dalsin, Ph.D. will join the Imbed leadership team as Vice President of Product Development. Dr. Dalsin will lead development of Imbed’s flagship product Microlyte® Ag wound dressings and product pipeline under quality control for new medical applications.  He brings more than 15 years’ experience developing novel biomaterials and medical devices.  Based on his doctoral work, Jeff helped cofound Nerites Corporation, a start-up that commercialized an innovative surgical adhesive and served as Director of Product Development.  In that role, Jeff wore many hats and gained broad start-up operational experience through the company’s successful acquisition in 2011.   Most recently, he led a start-up ultrasound technology company.  Jeff earned a B.S. in Life Sciences from the University of Illinois at Urbana-Champaign and M.S. and Ph.D. degrees from Northwestern University.

“Jeff served as a consultant to Imbed in the company’s early days on SBIR grants and quality management system. He is an excellent scientist and brings rigor of managing product development in start-up environment.  I am happy to welcome him back in a more formal role,” said Ankit Agarwal, Imbed’s President and CEO.

“I’ve known Ankit for several years now and have followed Imbed’s progress with great interest.  I am very happy to have the opportunity to again contribute to this team and assist in bringing a much-need wound care device to clinical users,” said Dalsin.

 

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. Company has a portfolio of products in development based on its patented polymeric Microfilm™ platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and support wound healing. Imbed is backed by venture capital group WISC Partners based in Madison, WI. Company has also received research grants from National Institutes of Health and National Science Foundation. For more information, visit www.imbedbio.com and follow facebook.com/imbedbio and @imbedbio on twitter.

CONTACT INFORMATION

Ankit Agarwal, CEO, Imbed Biosciences Inc.

ankit@imbedbio.com

Imbed Biosciences Secures ISO 13485:2003 Certification

IMBED BIOSCIENCES SECURES ISO 13485:2003 CERTIFICATION

 

Madison, WI, September 9, 2016 – Imbed Biosciences, a developer of advanced biomaterials and wound care devices, announced today that the company has received certification from British Standards Institution (BSI) Group America, Inc. that the company complies with the requirements of ISO 13485:2003 for an integrated Quality Management System across all functions of the business, from design and development to manufacturing and supply. The scope of the certificate includes the design, manufacture, and distribution of sterile wound dressings with medicinal substances.

“This is a crucially important step in bringing our first antimicrobial wound dressing product, MicroLyte AG, to global marketplace,” said Imbed’s President and CEO Ankit Agarwal.  “Furthermore, I am very pleased that our small team has been able to achieve this certification in a relatively short period of time in a very capital efficient manner.  ISO 13485 certification provides an important level of assurance to our customers and partners that Imbed can reliably provide high quality products.

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. Company has a portfolio of products in development based on its patented polymeric Microfilm™ platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and support wound healing. Imbed is backed by venture capital group WISC Partners based in Madison, WI. Company has also received research grants from National Institutes of Health and National Science Foundation. For more information, visit www.imbedbio.com and follow facebook.com/imbedbio and @imbedbio on twitter.

CONTACT INFORMATION

Ankit Agarwal, CEO, Imbed Biosciences Inc.

ankit@imbedbio.com

pdf-icon1

 

Imbed Receives FDA Clearance for Bacteria-Killing Wound Dressing

Imbed Receives FDA Clearance for Bacteria-Killing Wound Dressing

MADISON, WI (Aug 5, 2016) – Imbed Biosciences announced today that it has received clearance from the Food and Drug Administration (FDA) to market its patented Microfilm™ wound dressing—Microlyte® Ag, for human use. The dressing is an ultrathin hydrogel sheet as thin as human hair that is able to intimately conform to the contours of an underlying wound-bed. FDA has cleared Microlyte® Ag for management of hard to heal wounds under prescription use, and for small cuts and burns under over-the-counter use.

Like many dressings used today to treat burns and chronic wounds, Microlyte® Ag contains ionic and metallic silver to kill bacteria, but in much smaller quantities.

Photo: Open sore on dog

This chronic pressure sore on an Irish wolfhound received conventional treatment for more than three months at the UW–Madison School of Veterinary Medicine.

Photo: Dog's wound healing

Fourteen days after application of Microlyte, the sore is closed and well on its way to healing.

“Silver is an excellent antimicrobial agent,” said Ankit Agarwal, PhD, co-founder and CEO of the company, “as it is active against a broad range of bacteria and yeast. But the loadings of silver found in conventional silver dressings can be toxic to skin cells involved in wound healing”. Microlyte® Ag dressing contains as little as 1% of the silver found in other dressings in the clinics today, and is still effective in killing more than 99.99 percent of bacteria that it contacts, including some of the nastiest hospital-acquired superbugs such as methicillin-resistant staph aureus (MRSA) and vancomycin-resistant enterococcus (VRE).

Microlyte® Ag overcomes a key problem with existing dressings — stiffness. A wound has bumps and fissures that are hiding places for bacteria. The dressing inherently adheres to moist wound surfaces and is so thin and flexible that it conforms into the fissures, leading to the sweet combination of greater destruction of bacteria at much lower doses of silver.

 

Microlyte® Ag has several other advantages. It retains moisture yet is ultra-thin and breathable to maintain a moist wound healing environment. The slow release of silver means the dressing can remain in place to provide antimicrobial effect for several days. And because the material is a hydrogel (a water-based gel), it can simply be rinsed off as needed before replacement. Experience with animals shows that the ultra-thin dressing simply sloughs off as the wound heals, so it has to be only reapplied, not painfully removed from a wound. All of these advantages should reduce the need to change dressings, which can be painful enough to require sedation, especially in children.

“Reducing or eliminating dressing changes reduces the pain that the patient experiences,” says co-founder Michael Schurr, MD, chair of general surgery at the Mountain Area Health Education Center in Asheville, North Carolina. “It also reduces costs in supplies and reduces the burden to the health care system that supplies visiting nurses to do the dressing changes.”

Photo: Microlyte being injected into a pig

Imbed’s Microlyte dressing is applied to a wound on a pig. The ultra-thin dressing conforms to the wound, bringing the antimicrobial silver into direct contact with bacteria.

“We are seeing in a limited number of cases that it does provide us with a remarkable new tool for dealing with chronic wounds” in dogs and cats treated at the University of Wisconsin-Madison School of Veterinary Medicine, says Prof. Jonathan McAnulty, DVM, PhD, chair of Surgical Sciences. “We certainly have no reason to think that this will be different with humans,” add McAnulty, who is also a company co-founder. “The principles are same, and a lot of the problems are the same.”

The dramatic closure of wounds that have resisted months of conventional treatment, “suggests that chronic bacterial contamination of the wound surface, even when it looks relatively healthy, is a significant factor inhibiting healing in many cases,” McAnulty says. “Once we treat with Microlyte® Ag dressing, we start to see very dramatic closure of these wounds.” McAnulty says he’s starting to use Microlyte® earlier in treatment. “Certainly it seems appropriate for prevention of infection as well as management.”

The dressing will compete in North America in the $2-billion market sector of “advanced wound dressings,” which are used to treat diabetic ulcers, venous ulcers, burns, bedsores and other difficult wounds. “We are doing a limited release of Microlyte® Ag dressing in certain U.S. hospitals to study impact on different wound types”, said Agarwal. The company plans to reach the market through licensing agreements with hospital suppliers and is discussing commercial-scale production of Microlyte® Ag dressings.

“We are excited to support the launch of this new advanced wound care dressing that can help heal painful wounds in millions of patients in U.S.”, said David Guinther, a partner in the venture capital group– WISC partners. “We will continue to support executive team in recruiting global distribution partners and product line expansion”.

About Imbed Biosciences Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. Company has a portfolio of products in development based on its patented polymeric Microfilm™ platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and support wound healing. Imbed is backed by venture capital group WISC Partners based in Madison, WI. Company has also received research grants from National Institutes of Health and National Science Foundation. For more information, visit www.imbedbio.com and follow @Imbedbio on twitter.

About WISC Partners

Our mission at WISC Partners is to create wealth by helping a portfolio of well-chosen entrepreneurs in Wisconsin to build great companies that solve important customer problems. We accomplish this by injecting Strategic Operating Capital into these investments, which couples funding with company building experience, product and market expertise, corporate and business development networks, and highly engaged executive support. We are comprised of University of Wisconsin alumni, with offices in Madison, WI. For more information, please visit www.wiscpartners.com.

CONTACT INFORMATION

Ankit Agarwal, CEO, Imbed Biosciences Inc. ankit@imbedbio.com

Source UW Madison: http://news.wisc.edu/uw-madison-spinoff-gets-fda-ok-for-bacteria-killing-wound-dressing/

 

Imbed Bio Wins 2016 Wound Care Innovation Award in Bremen, Germany

04-banner_EWMA2016-www_01

 

Imbed Bio Wins 2016 Wound Care Innovation Award in Bremen, Germany

Bremen, Germany (May 12, 2016) – Imbed Biosciences announces that its microfilm wound dressing technology has today won the annual 2016 Wound Care Innovation Award at the European Wound Management Association (EWMA) conference in Bremen, Germany. About 6,000 medical professionals attended the conference, which is the largest such annual gathering in Europe. In total, more than 1000 scientific presentations took place during the three-day conference. More than 180 companies exhibited their newest products.

Imbed was one of the five finalists invited to present at the Wound Care Innovation Symposium for the grand prize, sponsored by CMC Consulting Group, EWMA and Lohmann & Rauscher. Each company made a 10 minutes presentation of their technological innovations before an esteemed panel of judges from the industry. The other finalist companies were Kerecis Ltd (Iceland), Birken AG (Germany), Inotec AMD Ltd (UK), and NuTech Medical (AL, USA).

Imbed presented its microfilm wound dressing technology platform, which is a transparent, thin, synthetic hydrogel film with a coating of ionic and metallic silver. When placed on a moist wound, microfilm dressing absorbs wound moisture and forms a conforming gel sheet that can provide antimicrobial barrier to infections for several days. Microfilm dressings contain 100 times less silver than competitor silver-based wound dressings in clinics, allowing them to be used on day one of any wound management plan without fear of silver staining or toxicity. The product is currently under review for regulatory clearance for human use.

About Imbed Biosciences Inc.

Imbed Biosciences is a privately held medical device company, located in Madison, WI. Imbed’s vision is to develop next-generation medical devices that can reduce patient pain and costs for management of burns, chronic wounds, hernia meshes, gastro-intestinal defects, and dural membranes. Company has a portfolio of products in development based on its synthetic and biodegradable thin films platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and promote wound healing. For more information, please visit www.imbedbio.com.

CONTACT INFORMATION
Ankit Agarwal, CEO
Imbed Biosciences Inc.
ankit@imbedbio.com

 

NIH to Showcase Imbed Bio in Innovation Zone at BIO 2016 in San Francisco, CA

BIO-2016-large

NIH to Showcase Imbed Bio in Innovation Zone at BIO 2016 in San Francisco, CA

Madison, WI (May 1, 2016)- Imbed Bio announces that it will exhibit at the 2016 Biotechnology Industry Organization (BIO) International Convention in San Francisco, CA from June 6-9, 2016. National Institutes of Health has selected to showcase Imbed Bio as one of its 50 top funded technologies. Imbed will host a kiosk in the Innovation Zone, an area of the exhibition floor that is dedicated to showcasing Small Business Innovation Research (SBIR) grantees.

SBIR grants provide early-stage funding for small businesses, and Imbed Bio currently has a $1.5M SBIR grant from the NIH to develop antimicrobial microfilm dressing with ionic and metallic silver for management of chronic wounds. Ankit Agarwal, PhD (CEO) will attend the convention and introduce company’s technology platform and pipeline products to potential customers, corporate partners and investors. Please contact Ankit Agarwal through the One-on-One Partnering System at the BIO Conference website if you would like to schedule a meeting at BIO 2016.

About Imbed Biosciences Inc.

Imbed Biosciences is a privately held medical device company, located in Madison, WI. Imbed’s vision is to develop next-generation medical devices that can reduce patient pain and costs for management of burns, chronic wounds, hernia meshes, gastro-intestinal defects, and dural membranes. Company has a portfolio of products in development based on its synthetic and biodegradable thin films platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and promote wound healing. For more information, please visit www.imbedbio.com.

CONTACT INFORMATION
Ankit Agarwal, CEO, Imbed Biosciences Inc.
ankit@imbedbio.com

Dow Chemist Joins Imbed Biosciences Team

Dow Chemist Joins Imbed Biosciences Team

Madison, WI, (December 1, 2014) – Imbed Biosciences, a developer of advanced biomaterials for surgical and wound care, announced today that Gaurav Pranami, Ph.D. will join the Imbed Biosciences team as Director of Research & Development.  Dr. Pranami will head expansion of Imbed’s bioactive polymeric microfilm technology and its transfer into scalable manufacturing processes. He brings 11 years of chemical and computational research experience to Imbed. He worked as senior engineer at Dow Chemical Company for the past 5 years on innovative inks, functional paper coatings, adhesives, textiles and non-wovens. Gaurav received his BS from the Indian Institute of Technology, Delhi, and his Ph.D. in Chemical Engineering from Iowa State University, Ames, IA, and did his post-doctoral research at University of Wisconsin-Madison.

“I have known Gaurav for several years and I am delighted that he is joining Imbed to lead research and development of microfilm technology,” said Ankit Agarwal, President and CEO of Imbed.  “His prior experience will help accelerate Imbed’s technical progress toward bringing our microfilm wound contact film dressings to market.”

“I have been closely monitoring Imbed’s progress for the past few years. I am excited for this opportunity to join the team and help bring the company’s exciting wound care technology to market,” said Pranami.

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. Company has a portfolio of products in development based on its patented polymeric Microfilm™ platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and support wound healing. Imbed is backed by venture capital group WISC Partners based in Madison, WI. Company has also received research grants from National Institutes of Health and National Science Foundation. For more information, visit www.imbedbio.com and follow @imbedbio on twitter.

CONTACT INFORMATION

Ankit Agarwal, CEO, Imbed Biosciences Inc.

ankit@imbedbio.com